Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 367 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07526519RecruitingPhase 1
Safety study of TL-003 for healthy adults and ulcerative colitis
This is an early-stage study testing a new drug called TL-003 to see if it's safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with ulcerative colitis (an inflammatory bowel disease) to understand if it might help reduce inflammation.
Perth, Western AustraliaAges 18–55 - NCT07563738RecruitingPhase 1/Phase 2
ODM-212 with cancer immunotherapy for advanced solid tumors
This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.
Irving, TexasAges 18 years+ - NCT07579234RecruitingPhase 3
New drug F182112 for hard-to-treat multiple myeloma
This trial tests a new drug called F182112 against standard treatments for multiple myeloma that has stopped responding to previous therapies. The goal is to see if F182112 works better and is safe for patients whose cancer has become resistant to multiple drug classes.
TianjingAges 18 years+ - NCT07589569RecruitingPhase 2
HRS-7058 for Advanced Pancreatic Cancer Treatment
This study tests a new drug called HRS-7058 in patients with pancreatic cancer that has spread or cannot be removed by surgery. You may qualify if your cancer has already been treated with at least one prior therapy and you have measurable disease on imaging.
Nanjing, JiangsuAges 18–75 - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT07599592RecruitingEarly Phase 1
Ultrasound Treatment for Essential Tremor
This early-stage study tests whether focused ultrasound waves can safely reduce hand tremors in people with essential tremor. The ultrasound is applied from outside the skin without surgery, and researchers want to see if it helps calm unwanted shaking.
Los Angeles, CaliforniaAges 18–90 - NCT07610772RecruitingPhase 1
Safety study of a new hepatitis B antibody for hepatitis D
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
AarhusAges 18–70 - NCT07632235RecruitingPhase 1/Phase 2
Celecoxib with immunotherapy for bile duct cancer
This trial tests whether adding celecoxib (an anti-inflammatory pill) to pembrolizumab (an immunotherapy) and chemotherapy helps treat intrahepatic cholangiocarcinoma—a type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than the standard two-drug approach.
ShanghaiAges 18 years+ - NCT07639944Recruiting
REN Device Study for Jaw Pain and Headaches
This study tests whether a treatment called REN can help reduce headaches and jaw pain caused by temporomandibular disorders (TMD). You would use the REN device at home on your smartphone or tablet over several months.
Ridgeland, MississippiAges 12 years+ - NCT07644832RecruitingPhase 1/Phase 2
New Blood-Clotting Injection for Hemophilia and Factor VII Deficiency
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
ChangshaAges 18–65 - NCT07650708RecruitingPhase 4
Eye Dryness After LASIK Surgery With a New Dry Eye Treatment
This study tests whether a new eye lubricant called Miebo, given before LASIK vision correction surgery, reduces dry eye symptoms afterward. If you have mild-to-moderate dry eyes and need LASIK, this trial may help you stay more comfortable during your recovery.
Bozeman, MontanaAges 18 years+ - NCT07655115RecruitingPhase 3
Arbaclofen for Autism: Brain Wave Study
This study tests a medicine called arbaclofen to see how it affects brain waves in people with autism. It includes a brief double-blind crossover phase followed by a 10-week open-label treatment period.
ParisAges birth–64 years - NCT07668453RecruitingPhase 2
Adebrelimab plus chemo for advanced bile duct cancer
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT07657052Enrolling by invitation
Long-term safety and effectiveness of XH-S003 for PNH
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
Tianjin, JinanAges 18 years+ - NCT07580586RecruitingPhase 1
Study of BV100's effect on polymyxin B in healthy volunteers
This early-stage study tests how a new drug called BV100 affects how your body processes polymyxin B, an antibiotic. Researchers want to understand how these two drugs interact so they can develop safer treatments.
ViennaAges 18–55 - NCT07401823Enrolling by invitationPhase 2
Long-term follow-up study for sickle cell disease treatment
This study is a follow-up for people with sickle cell disease who already saw a benefit in fetal hemoglobin from the earlier Pioneer study. It tests the long-term safety and effects of the study drug pociredir (also called FTX-6058) while allowing most standard sickle cell treatments except hydroxyurea.
Little Rock, ArkansasAges 18 years+ - NCT07393373Enrolling by invitationPhase 2
Long-term study of infigratinib in children with hypochondroplasia
This study is for children with hypochondroplasia who already completed the ACCEL 2/3 trial. It tests the long-term safety and effects of the study drug infigratinib, and gives continued access to the treatment.
Oakland, CaliforniaAges 3–18 - NCT07217860Enrolling by invitationPhase 3
Long-term safety study of azetukalner for bipolar depression
This study is looking at the long-term safety of azetukalner for people with bipolar I or II depression who have already completed a previous trial of this drug. It is an open-label study, meaning everyone will receive the active medication.
Little Rock, ArkansasAges 18–75 - NCT07209332Enrolling by invitationPhase 2
Long-term safety study of WVE-N531 for Duchenne muscular dystrophy
This trial is for people who have already taken WVE-N531 in an earlier study. It continues to check the medicine's safety and effects over a longer period.
AmmanAges Any age - NCT07168824Enrolling by invitation
Can a probiotic improve memory in adults with mild cognitive decline?
This trial tests whether a daily probiotic called Lacticaseibacillus paracasei PS23 can help improve thinking and memory in adults aged 50 to 85 who feel their memory is slipping but do not have dementia or Alzheimer's disease.
TaoyuanAges 50–85 - NCT07162441RecruitingPhase 1
Drug interaction study in healthy volunteers
This trial tests two experimental drugs in healthy adults to see how they interact with each other and to check their safety. It involves taking the drugs in a specific order over multiple days.
Seoul, Gwanak-guAges 19 years+ - NCT06867107Enrolling by invitationPhase 2
Long-term follow-up study of SAT-3247 for Duchenne
This is a long-term follow-up study for people with Duchenne muscular dystrophy who already took part in a previous SAT-3247 trial. It checks how safe and effective the treatment stays over a longer time.
Melbourne, VictoriaAges 18–40 - NCT06558201Enrolling by invitation
Open-label extension for completers of earlier study
This trial is for people who finished a 12-week study (NCT06221852) and still meet its original requirements. It offers continued access to the study treatment.
Belmont, MassachusettsAges 18–45 - NCT06549400Enrolling by invitationPhase 3
Study on long-term safety of mexiletine for myotonic dystrophy
This study tests if a daily capsule of mexiletine is safe and helpful over 26 weeks for people with myotonic dystrophy type 1 or 2. It's for people who finished a previous related study and want to continue treatment.
LeuvenAges 16 years+
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 367 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.